|
1）Behfar A, Crespo-Diaz R, Terzic A, et al. Cell therapy for cardiac repair — lessons from clinical trials. Nat Rev Cardiol. 2014; 11: 232-46
|
|
|
|
2）Menasche P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008; 117: 1189-200
|
|
|
|
|
|
3）Roell W, Lewalter T, Sasse P, et al. Engraftment of connexin 43-expressing cells prevents postinfarct arrhythmia. Nature. 2007; 450: 819-24
|
|
|
|
|
|
4）Nakamura Y, Asakura Y, Piras BA, et al. Increased angiogenesis and improved left ventricular function after transplantation of myoblasts lacking the MyoD gene into infarcted myocardium. PLoS One. 2012; 7: e41736
|
|
|
|
|
|
5）Pätilä T, Miyagawa S, Imanishi Y, et al. Comparison of arrhythmogenicity and proinflammatory activity induced by intramyocardial or epicardial myoblast sheet delivery in a rat model of ischemic heart failure. PLoS One. 2015; 10: e0123963
|
|
|
|
|
|
6）Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance STelevation infarct regeneration) trial. Circulation. 2006; 113: 1287-94
|
|
|
|
|
|
7）Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011; 100: 925-34
|
|
|
|
|
|
8）Delewi R, Hirsch A, Tijssen JG, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J. 2014; 35: 989-98
|
|
|
|
|
|
9）Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012; 307: 1717-26
|
|
|
|
|
|
10）Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012; 308: 2380-9
|
|
|
|
|
|
11）Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011; 306: 2110-9
|
|
|
|
|
|
12）Surder D, Manka R, Lo Cicero V, et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation. 2013; 127: 1968-79
|
|
|
|
|
|
13）Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311: 62-73
|
|
|
|
|
|
14）Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012; 308: 2369-79
|
|
|
|
|
|
15）Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61: 2329-38
|
|
|
|
|
|
16）Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: At the heart of regeneration. J Mol Cell Cardiol. 2011; 50: 296-303
|
|
|
|
|
|
17）Tallini YN, Greene KS, Craven M, et al. c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci U S A. 2009; 106: 1808-13
|
|
|
|
|
|
18）Zaruba MM, Soonpaa M, Reuter S, et al. Cardiomyogenic potential of C-kit(+)-expressing cells derived from neonatal and adult mouse hearts. Circulation. 2010; 121: 1992-2000
|
|
|
|
|
|
19）van Berlo JH, Kanisicak O, Maillet M, et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature. 2014; 509: 337-41
|
|
|
|
|
|
20）Bolli R, Chugh AR, D,Amario D, et al. Cardiac stem cells in patients with ischemic cardiomyo-pathy (SCIPIO): initial results of a randomized phase 1 trial. Lancet. 2011; 378: 1847-57
|
|
|
|
|
|
21）Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014; 63: 110-22
|
|
|
|
|
|
22）Mummery CL, Zhang J, Ng ES, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012; 111: 344-58
|
|
|
|
|
|
23）Maher KO, Xu C. Marching towards regenerative cardiac therapy with human pluripotent stem cells. Discov Med. 2013; 15: 349-56
|
|
|
|
|
|
24）Lalit PA1, Hei DJ, Raval AN, et al. Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. Circ Res. 2014; 114: 1328-45
|
|
|
|
|
|
25）Fernandes S, Naumova AV, ZhuWZ, et al. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J Mol Cell Cardiol. 2010; 49: 941-9
|
|
|
|
|
|
26）Shiba Y, Filice D, Fernandes S, et al. Electrical integration of human embryonic stem cell-derived cardiomyocytes in a guinea pig chronic infarct model. J Cardiovasc Pharmacol Ther. 2014; 19: 368-81
|
|
|
|
|
|
27）Chong JJ, Yang X, Don CW, et al. Human embryonicstem- cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014; 510: 273-7
|
|
|
|
|
|
28）Kawamura M, Miyagawa S, Miki K, et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2012; 126: S29-S37
|
|
|
|
|
|
29）Hirt MN, Hansen A, Eschenhagen T. Cardiac Tissue Engineering State of Art. Circ Res. 2014; 114: 354-67
|
|
|
|
|
|
30）Hong KU1, Guo Y2, Li QH2, et al. c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart. PLoS One. 2014; 9: e96725
|
|
|
|
|
|
31）Keith MC, Bolli R. “String theory” of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res. 2015; 116: 1216-30
|
|
|
|
|
|
32）Reinecke H, Zhang M, Bartosek T, et al. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 1999; 100: 193-202
|
|
|
|
|
|
33）Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006; 367: 113-21
|
|
|
|
|
|
34）Beitnes JO, Hopp E, Lunde K, et al. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart. 2009; 95: 1983-9
|
|
|
|
|
|
35）Assmus B, Rolf A, Erbs S, et al. Clinical 0utcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010; 3: 89-96
|
|
|
|
|
|
36）Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011; 32: 1736-47
|
|
|
|
|
|
37）Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006; 355: 1222-32
|
|
|
|
|